Figure 1
SCCA-IgM serological levels in patients with HCV infection and cirrhosis
| SCCA-IgM | DB 1 | DB 2 | DB 3 | DB 4 | DB 5 | DB 6 | TOT |
|---|---|---|---|---|---|---|---|
| ≥0 AU/mL | 272 | 127 | 67 | 76 | 24 | 31 | 597 |
| >50 AU/mL | 206 | 106 | 61 | 32 | 22 | 31 | 458 |
| >200 AU/mL | 121 | 52 | 29 | 51 | 7 | 18 | 278 |
| >300 AU/mL | 88 | 37 | 20 | 34 | 7 | 10 | 196 |
| >500 AU/mL | 67 | 24 | 16 | 19 | 5 | 2 | 133 |
| >600 AU/mL | 60 | 18 | 13 | 13 | 3 | 2 | 109 |
number of HCC and relative costs and savings associated with the monitoring of HCV-cirrhotic patients in Italy_
| Annual cost of US only every 6 months | €46.516.400 |
| Annual cost of SCCA-IgM analysis | €4.008.069 |
| Costs saved by doing 1 US/year instead of 2 | €5.247.488 |
| Net costs of SCCA-IgM+US/year | €45.276.981 |
| Annual saving of SCCA-IgM+US vs. US only | €1.239.419 |
| HCC identified/year | €11.974 |
| Cost of US only/HCC identified | €3.885 |
| Cost of SCCA-IgM+US/HCC identified | €3.781 |
| Saving/HCC identified | €104 |
SCCA-IgM levels and timing of HCC development in patients with HCV infection and cirrhosis
| SCCA-IgM | HCC 12 months % | HCC 6 months % | HCC 4 months % |
|---|---|---|---|
| ≤50 AU/mL | 0/16 | 0/16 | 0/16 |
| >50 AU/mL | 24/287 | 11/287 | 10/287 |
| >500 AU/mL | 7/63 | 5/63 | 5/63 |